| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbadc41aa91592752369d88100f96411 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
1989-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de54f9b3d29ddccfbebacd9e703e220
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f65e61c12e00fbd178c9a9f342a8a3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3758784ba524383aeec62a6299315929
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe0d135f825258d21523ad9b564a8b1a |
| publicationDate |
1989-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-8906544-A1 |
| titleOfInvention |
Heteroligating antibodies and therapeutic uses thereof |
| abstract |
This invention discloses a method of utilizing and augmenting a patient's own endogenously-produced bioactive compounds through the judicious use of specially designed multifunctional antibodies. In particular, the invention describes the use of heteroligating antibodies produced by polydomas in which one antigen binding site is reactive with a target and the other site is capable of initiating, or promoting the use of, at least one endogenous bioactive compound directed against the target. In another embodiment of this invention, heteroligating antibodies are described that bind a bioactive compound such as lymphokine or a metabolite and a target ligand such as a cancer cell. Specifically, heteroantibodies are described binding interferon-gamma and tumor cells. Other antibodies bind both tissue plasminogen activator and platelets. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6258358-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9203145-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6248332-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7166423-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9006133-A1 |
| priorityDate |
1988-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |